Ultragenyx shares plunge after apazunersen Phase 3 misses endpoints
Ultragenyx Pharmaceutical’s shares fell after Phase 3 apazunersen for Angelman missed key endpoints, triggering a program review and cost cuts. Positive GENGLYCOS data and upcoming UX111 and gene-therapy readouts keep focus on the pipeline.
Ultragenyx Pharmaceutical, Inc. (NASDAQ:RARE) plunged after apazunersen in Phase 3 for Angelman missed key endpoints. The company said it will review the program and cut costs, while positive GENGLYCOS (DTX401) data and upcoming UX111 and gene-therapy readouts keep the pipeline in play. Barclays trimmed its price tar...